January 23, 2024 – Carbon Medical Technologies, Inc. (CMT), a manufacturer of pyrolytic carbon-coated medical devices used in biopsy procedures, for radiation therapy, and to treat stress urinary incontinence, is proud to announce that it has been awarded a group purchasing agreement with Premier, Inc. effective February 1, 2024. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BiomarC Fiducial Marker Product Line.
Fiducial markers are radiographically visible marking devices used to surgically mark an area of interest for radiation treatment or future surgical procedures. Fiducial markers are placed in or around a tumor (or cavity) to accurately visualize and target the area of interest with radiation therapy while minimizing the damage to healthy tissue in the treatment process, thus improving patient outcomes.
The BiomarC Fiducial Marker Product Line is compatible with all forms of radiation therapy and provides maximum versatility for modalities and treatments such as IGRT/IMRT, proton therapy, CT, CBCT, MRI and portal imaging. Other advantages of the BiomarC Fiducial Marker Product Line include:
- Exceptional biocompatibility due to the pyrolytic carbon coating technology.
- Unique materials provide precise marking while minimizing artifact – saving time and improving accuracy.
- Reliable marker shape that minimizes movement after placement.
- Durable with no flaking or chipping of the pyrolytic carbon coating over time.
- Complete portfolio of 510(k) cleared fiducial markers available for any area of the body.
“The collaboration with Premier is an incredible opportunity for Carbon Medical Technologies to promote increased use of fiducial markers for higher targeted radiation doses and better patient outcomes in the growing segment of Image Guided Radiotherapy and other Radiation Therapy techniques”, says Stephanie Kent, CEO at CMT.
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and approximately 300,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.
For more information about CMT’s BiomarC Fiducial Marker Product Line, please visit www.carbonmed.com or contact 1-888-207-0262.
About Carbon Medical Technologies, Inc.
Carbon Medical Technologies, Inc. (CMT) is a privately held company formed in 1994 to design, develop, and manufacture permanent human implantable products utilizing pyrolytic carbon. CMT operates a fully functional pyrolytic carbon coating facility and has developed multiple FDA approved, cleared to market, and CE Marked products. Currently, the pyrolytic carbon coating technology is incorporated into BiomarC implantable tissue markers developed for biopsy site marking, the BiomarC fiducial marker product line for radiation therapy treatment planning, and an injectable bulking agent called Durasphere, which is used for the treatment of stress urinary incontinence in women, and additional indications outside of the US. CMT also provides product development, contract manufacturing, and regulatory consulting for medical device companies. The company is a medical device manufacturer with ISO 13485 certified and cGMP compliant quality systems, maintains three different sterilization method validations, and does final product assembly and packaging in an ISO Class 7 clean room environment.